Compare Gilead Sciences, Inc. (GILD) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Teladoc Health Inc — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Teladoc Health Inc trades at $9.54 (market cap $1.75B). The key difference: Gilead Sciences, Inc. is far larger — about 93.4× Teladoc Health Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| GILD | TDOC | |
|---|---|---|
Market Cap | $163.51B | $1.75B |
Sector | Health | Health |
52-Week High | $155.80 | $9.72 |
52-Week Low | $108.22 | $4.47 |
Enterprise Value | $178.05B | $2.04B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TDOC trades at $9.56, up 3.13% with bullish technical signals from moving averages. The company reported mixed Q1 2026 earnings, missing expectations with a -$0.36 EPS, but maintains strong revenue of $2.53B and a gross margin of 69.29%. Recent partnership expansions with Walmart highlight growth initiatives, though net losses persist at -$200.32M. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.
The outlook remains cautious due to ongoing net losses and negative cash flow trends, with net cash flow at -$517.24M in 2025. Key risks include competitive pressures and execution challenges, but cost-cutting and market expansion could support recovery. Investors should weigh the low P/S ratio of 0.69 against profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
